Evidence map›Paper›PMID 26705757›Full record

ArticleCurrent treatment options in neurology2016

Use of Cannabinoids for Spasticity and Pain Management in MS.

Hardeep Chohan, Ariele L Greenfield, Vijayshree Yadav, Jennifer Graves

Abstract read
PubMed Publisher
In one paragraph

Article in Current treatment options in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 36 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hardeep ChohanDepartment of Neurology, University of California, San Francisco, 350 Parnassus Avenue, 304 A, San Francisco, CA, 94117, USA. Hardeep.Chohan@ucsf.edu.
Ariele L GreenfieldDepartment of Neurology, University of California, San Francisco, 350 Parnassus Avenue, 304 A, San Francisco, CA, 94117, USA.
Vijayshree YadavDepartment of Neurology, Oregon Health and Science University, Portland, OR, USA.
Jennifer GravesDepartment of Neurology, University of California, San Francisco, 350 Parnassus Avenue, 304 A, San Francisco, CA, 94117, USA.
University of California, San Francisco · USOregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementSeveral randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies.

Indexed as

CannabidiolCannabinoidsMultiple sclerosisPainSpasticityTetrahydrocannabinol

Identifiers

PMID26705757
OpenAlexW2211144186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.